A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Psoriasis With a Side of Arthritis Biologics also represent the first choice of systemic therapy for Oyetewa Asempa, MD, of Baylor College of Medicine in Houston.

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Patients with psoriasis who had low body surface area (BSA) involvement experienced similarly poor QOL and symptom burden compared to patients with higher BSA.

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Switching from adalimumab to guselkumab led to rapid improvement of a paradoxical pustular psoriasis unresponsive to topical steroids.

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the ...

Guselkumab significantly improves psoriasis severity and quality of life compared with placebo in patients with skin of color.